Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.55 |
| ▸ | CCND1 | P24385 | 19/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 14/20 | 0.55 |
| ▸ | CDK2 | P24941 | 14/20 | 0.55 |
| ▸ | CCND2 | P30279 | 8/20 | 0.52 |
| ▸ | CCND3 | P30281 | 8/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 12/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.47 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553803 | 0.91 | CDK4 (0.61) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL15788027 | 0.78 | CDK4 (0.41) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL15036059 | 0.77 | CDK4 (0.52) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL15036072 | 0.76 | CDK4 (0.58) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL15785319 | 0.74 | CDK4 (0.56) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL11977052 | 0.73 | CDK4 (0.74) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL5900790 | 0.72 | CDK4 (0.62) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL15785216 | 0.71 | TNK2 (0.51) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL13553480 | 0.71 | CDK4 (0.52) | CDK4CCND1CCNA2CDK2CCND2 | |
| SCHEMBL15035078 | 0.71 | CDK4 (0.52) | CDK4CCND1CCNA2CDK2CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CCNA2 2011/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | CDK4 98/4885CCND1 2208/4885CCNA2 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.